Published in Ann Rheum Dis on February 17, 2011
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis (2016) 1.42
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis (2013) 1.31
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis (2014) 1.27
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis (2014) 1.15
[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis]. Z Rheumatol (2012) 1.06
Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2012) 1.05
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol (2011) 1.04
Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2013) 0.94
Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol (2013) 0.93
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis (2015) 0.93
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes (2014) 0.88
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics (2014) 0.86
Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study. Arthritis (2015) 0.86
Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int (2011) 0.85
Combination therapy: the next opportunity and challenge of medicine. J Transl Med (2011) 0.85
Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int (2015) 0.84
Lymphotoxin α revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther (2011) 0.84
The importance of rheumatology biologic registries in Latin America. Rheumatol Int (2012) 0.82
The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. BMC Med Inform Decis Mak (2014) 0.81
Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol (2015) 0.80
Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes. Arthritis Res Ther (2013) 0.79
Effect of γ-tocotrienol in counteracting oxidative stress and joint damage in collagen-induced arthritis in rats. Exp Ther Med (2014) 0.78
Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. Rheumatol Ther (2015) 0.78
Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise. J Res Med Sci (2011) 0.77
Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord (2016) 0.77
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag (2015) 0.77
Effect of Bizhongxiao decoction and its dismantled formulae on IL-1 and TNF levels in collagen-induced arthritis in rat synovial joints. Theor Biol Med Model (2012) 0.76
Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clin Rheumatol (2015) 0.76
Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics (2015) 0.76
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol (2015) 0.76
Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open (2015) 0.76
Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica (2016) 0.75
Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis? Patient Prefer Adherence (2016) 0.75
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs. Rheumatol Ther (2015) 0.75
The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol (2016) 0.75
Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open (2017) 0.75
Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther (2016) 0.75
Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis. PLoS One (2015) 0.75
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. Rheumatol Ther (2017) 0.75
A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience. Clin Rheumatol (2013) 0.75
Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol (2017) 0.75
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol (2017) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis (2002) 3.10
The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol (2005) 2.88
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf (2009) 1.96
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) (2004) 1.72
Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol (2004) 1.66
British Society for Rheumatology Biologics Register. Ann Rheum Dis (2003) 1.63
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum (2008) 1.60
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther (2006) 1.33
Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis (2009) 1.30
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther (2008) 1.24
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol (2005) 1.23
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) (2007) 1.19
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther (2009) 1.15
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis (2008) 1.02
Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol (2007) 0.99
Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol (2005) 0.99
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol (2010) 0.98
Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology (2008) 0.93
Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum (2004) 0.90
A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol (2009) 0.88
Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol (2008) 0.84
The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum (2004) 0.83
Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) (2002) 0.82
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Prevalence, incidence and nature of prescribing errors in hospital inpatients: a systematic review. Drug Saf (2009) 3.34
Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract (2007) 3.16
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework. BMJ (2014) 2.92
Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother (2008) 2.84
The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review. Drug Saf (2009) 2.81
The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol (2005) 2.48
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet (2009) 2.48
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med (2011) 2.37
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2003) 2.20
Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum (2004) 2.19
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Low back pain in schoolchildren: occurrence and characteristics. Pain (2002) 2.02
Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. Arthritis Care Res (Hoboken) (2013) 2.01
Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother (2011) 1.94
Prevalence and nature of medication administration errors in health care settings: a systematic review of direct observational evidence. Ann Pharmacother (2013) 1.92
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976) (2003) 1.79
Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol (2008) 1.78
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2010) 1.77
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum (2006) 1.72
Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis. JAMA (2013) 1.67
Predictors of low back pain in British schoolchildren: a population-based prospective cohort study. Pediatrics (2003) 1.67
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum (2002) 1.66
Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol (2009) 1.60
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol (2009) 1.60
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.56
National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol (2003) 1.56
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.55
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Determinants of the uptake of medicines use reviews (MURs) by community pharmacies in England: a multi-method study. Health Policy (2008) 1.53
Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol (2005) 1.52
The challenge of integrating community pharmacists into the primary health care team: a case study of local pharmaceutical services (LPS) pilots and interprofessional collaboration. J Interprof Care (2008) 1.51
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) (2010) 1.43
Incidence of cancer among UK Gulf war veterans: cohort study. BMJ (2003) 1.43
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis (2005) 1.36
Integration and differentiation: a conceptual model of general practitioner and community pharmacist collaboration. Res Social Adm Pharm (2011) 1.35
The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis (2012) 1.30
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) (2010) 1.30
Predictors of hip joint replacement in new attenders in primary care with hip pain. Br J Gen Pract (2003) 1.29
Causes of medication administration errors in hospitals: a systematic review of quantitative and qualitative evidence. Drug Saf (2013) 1.29
Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. Spine (Phila Pa 1976) (2007) 1.29
Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum (2004) 1.27
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis (2006) 1.25
Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2007) 1.24
When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2004) 1.24
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.24
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis (2009) 1.22
Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine (2007) 1.22
Understanding the attitudes of hospital pharmacists to reporting medication incidents: a qualitative study. Res Social Adm Pharm (2012) 1.21
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) (2013) 1.21